KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: A cohort study

BMJ Open

Volumn 4, Issue 5, 2014, Pages

  Negru, Serban ^a   Papadopoulou, Eirini ^b   Apessos, Angela ^b   Stanculeanu, Dana Lucia ^c   Ciuleanu, Eliade ^d   Volovat, Constantin ^e   Croitoru, Adina ^f   Kakolyris, Stylianos ^g   Aravantinos, Gerasimos ^h   Ziras, Nikolaos ⁱ   Athanasiadis, Elias ^j   Touroutoglou, Nikolaos ^k   Pavlidis, Nikolaos ^l   Kalofonos, Haralabos P ^m   Nasioulas, George ^b  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Department of Molecular Biology GENEKOR   (Greece)

^c Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^d THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^e Centrul de Oncologie Medicala   (Romania)

^f FUNDENI CLINICAL INSTITUTE   (Romania)

^g UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^h AGII ANARGIRI CANCER HOSPITAL   (Greece)

ⁱ METAXA CANCER HOSPITAL   (Greece)

^j MITERA HOSPITAL   (Greece)

^k INTERBALKAN MEDICAL CENTER   (Greece)

^l UNIVERSITY OF IOANNINA   (Greece)

^m UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; RAS PROTEIN; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PROTEIN P21;

ALLELE; ARTICLE; CANCER PATIENT; CODON; COHORT ANALYSIS; COLORECTAL CARCINOMA; EXON; GENE FREQUENCY; GENE MUTATION; GREECE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PIACENZIAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE; COLORECTAL TUMOR; DNA DENATURATION; GENETICS; MOLECULAR DIAGNOSIS; MUTATION; PROCEDURES; ROMANIA; VALIDATION STUDY;

COHORT STUDIES; COLORECTAL NEOPLASMS; GREECE; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NUCLEIC ACID DENATURATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); ROMANIA;

EID: 84901439503     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004652     Document Type: Article

References (24)

1. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010;19:157-63.
2. Heinemann V, Stintzing S, Kirchner T, et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009;35:262-71.
3. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50:307-12.
4. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
5. Pietrantonio F, Perrone F, Biondani P, et al. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: clinical outcome and biomarkers of efficacy. Cancer Biol Ther 2013;14:1098-103.
6. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
7. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013;258:619-272.
8. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295.
9. Borràs E, Jurado I, Hernan I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 2011;11:406.
10. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS ONE 2010;5:e8802.
11. Belli C, Bowen DJ, De BRAFi C, et al. A single, multiplex analysis for all relevant activating NRAS gene mutations using heteroduplex generators. Br J Haematol 2004;126:602-5. (Pubitemid 39093104)
12. Hatzaki A, Razi E, Anagnostopoulou K, et al. A modified mutagenic PCR-RFLP method for K-RAS codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes 2001;15:243-7. (Pubitemid 33104992)
13. Guedes JG, Veiga I, Rocha P, et al. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer 2013;13:169.
14. Ney JT, Froehner S, Roesler A, et al. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med 2012;136:983-92.
15. Simi L, Pratesi N, Vignoli M, et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008;130:247-53.
16. Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
17. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
18. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
19. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
20. Ciardiello F, Tejpar S, Normanno N, et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 2011;6:133-45.
21. Chaiyapan W, Duangpakdee P, Boonpipattanapong T, et al. Somatic mutations of K-RAS and BRAF in Thai colorectal cancer and their prognostic value. Asian Pac J Cancer Prev 2013;14:329-32.
22. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-21.
23. Catalogue of Somatic Mutations in Cancer. [http://cancer.sanger.ac.uk]
24. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.